Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Frequently asked questions
What sector does Oculis Holding AG (OCS) operate in?
Oculis Holding AG belongs to the Other sector and operates in the Biotechnology industry.
What is Oculis Holding AG (OCS) current stock price?
As of the latest data, Oculis Holding AG stock price is ISK 1,605, with a previous close of ISK 1,600. Oculis Holding AG gained ISK 5 in the last trading session, representing a 0.31% increase.
What is Oculis Holding AG (OCS) current market capitalization?
Oculis Holding AG market cap is approximately 96.92 billion.
What is Oculis Holding AG (OCS) Earnings Per Share (EPS)?
The trailing EPS is -ISK 268.
Does Oculis Holding AG (OCS) pay dividends?
No. Oculis Holding AG does not pay a dividend.
When is Oculis Holding AG (OCS) next earnings report?
Oculis Holding AG is expected to release its next earnings report on March 31, 2026.
What is Oculis Holding AG (OCS) beta (volatility) score?
Oculis Holding AG has a beta of 0.306, indicating lower volatility than the overall market.
